These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 15796965)

  • 1. Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16.
    Kuroda H; Moritake H; Sawada K; Kuwahara Y; Imoto I; Inazawa J; Sugimoto T
    Cancer Genet Cytogenet; 2005 Apr; 158(2):172-9. PubMed ID: 15796965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.
    Uno K; Takita J; Yokomori K; Tanaka Y; Ohta S; Shimada H; Gilles FH; Sugita K; Abe S; Sako M; Hashizume K; Hayashi Y
    Genes Chromosomes Cancer; 2002 May; 34(1):33-41. PubMed ID: 11921280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.
    Biegel JA; Tan L; Zhang F; Wainwright L; Russo P; Rorke LB
    Clin Cancer Res; 2002 Nov; 8(11):3461-7. PubMed ID: 12429635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.
    Rousseau-Merck MF; Versteege I; Legrand I; Couturier J; Mairal A; Delattre O; Aurias A
    Cancer Res; 1999 Jul; 59(13):3152-6. PubMed ID: 10397258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation.
    Fujisawa H; Misaki K; Takabatake Y; Hasegawa M; Yamashita J
    J Neurooncol; 2005 Jun; 73(2):117-24. PubMed ID: 15981100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities.
    Bourdeaut F; Fréneaux P; Thuille B; Lellouch-Tubiana A; Nicolas A; Couturier J; Pierron G; Sainte-Rose C; Bergeron C; Bouvier R; Rialland X; Laurence V; Michon J; Sastre-Garau X; Delattre O
    J Pathol; 2007 Feb; 211(3):323-30. PubMed ID: 17152049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical study as a tool in differential diagnosis of pediatric malignant rhabdoid tumor.
    Machado I; Noguera R; Santonja N; Donat J; Fernandez-Delgado R; Acevedo A; Baragaño M; Navarro S
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):150-8. PubMed ID: 19770707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR.
    Kohashi K; Oda Y; Yamamoto H; Tamiya S; Izumi T; Ohta S; Taguchi T; Suita S; Tsuneyoshi M
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):817-24. PubMed ID: 17486366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant rhabdoid-tumor cell line showing neural and smooth-muscle-cell phenotypes.
    Sugimoto T; Hosoi H; Horii Y; Ishida H; Mine H; Takahashi K; Abe T; Ohta S; Sawada T
    Int J Cancer; 1999 Aug; 82(5):678-86. PubMed ID: 10417765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
    Caramel J; Medjkane S; Quignon F; Delattre O
    Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.
    Versteege I; Sévenet N; Lange J; Rousseau-Merck MF; Ambros P; Handgretinger R; Aurias A; Delattre O
    Nature; 1998 Jul; 394(6689):203-6. PubMed ID: 9671307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
    Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
    Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features.
    Cho YM; Choi J; Lee OJ; Lee HI; Han DJ; Ro JY
    Pathol Int; 2006 Nov; 56(11):702-6. PubMed ID: 17040295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel germ-line deletion of SNF5/INI1/SMARCB1 gene in neonate presenting with congenital malignant rhabdoid tumor of kidney and brain primitive neuroectodermal tumor.
    Kusafuka T; Miao J; Yoneda A; Kuroda S; Fukuzawa M
    Genes Chromosomes Cancer; 2004 Jun; 40(2):133-9. PubMed ID: 15101046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of the rhabdoid predisposition syndrome in a child: a novel germline hSNF5/INI1 mutation and absence of c-myc amplification.
    Fujisawa H; Takabatake Y; Fukusato T; Tachibana O; Tsuchiya Y; Yamashita J
    J Neurooncol; 2003 Jul; 63(3):257-62. PubMed ID: 12892231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas.
    Perry A; Fuller CE; Judkins AR; Dehner LP; Biegel JA
    Mod Pathol; 2005 Jul; 18(7):951-8. PubMed ID: 15761491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
    Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
    Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
    Kuwahara Y; Wei D; Durand J; Weissman BE
    Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization.
    Medjkane S; Novikov E; Versteege I; Delattre O
    Cancer Res; 2004 May; 64(10):3406-13. PubMed ID: 15150092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rhadboid tumours: hSNF/INI1 deficient cancers of early childhood with aggressive behaviour].
    Bourdeaut F; Dufour C; Delattre O
    Bull Cancer; 2010 Jan; 97(1):37-45. PubMed ID: 20080459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.